Bidil: profile and news

Envisioning 2.0 Launches First Blogosphere â€œConversationâ€? ... 06 Mar 2006
...was inspired to start this conversation partly because of the intense debate that accompanied the Food and Drug Administrationâ€™s approval of BiDil, which was ... - PR Web (press release),

BiDil Sales Bite NitroMed Mar 2, 2006
The Lexington, Mass.-based company said Thursday that efforts to improve sales of the drug BiDil include stepping up negotiations with insurers and converting ... - TheStreet.com

Biomed Rounds: NitroMed places bet on BiDil, but is the timing and ... Feb 20, 2006
...years. In mid-2005 it won approval from the Food and Drug Administration for a drug called BiDil, a medication for heart failure. ... - Boston Mass High Tech,

NitroMed Reports Financial Results for Fourth Quarter and Full ... Mar 2, 2006
Of total revenue, BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) product sales accounted for $3.3 million during the fourth quarter, $4.5 million ... - Genetic Engineering News,

NitroMed falls after downgrade Mar 3, 2006
Shares of the maker of BiDil, a drug that combats cardiovascular disease in African Americans, closed down 77 cents, or 8.1 percent, to $8.72 on the Nasdaq ... - BusinessWeek

NitroMed to Present at the SG Cowen & Co. Health Care Conference ... Feb 28, 2006
Ph.D., NitroMed's President and Chief Executive Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide ... - Genetic Engineering News,

Multimedia News Release - Heart Failure Society Supports the Use ... Feb 23, 2006
This combination is available as a proprietary fixed-dose formulation known as BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), developed and ... - PR Newswire (press release),

Novell earnings fall short of estimates Mar 3, 2006
NitroMed Inc., maker of BiDil, a drug that combats cardiovascular disease in African-Americans, reported a wider fourth-quarter loss, hurt by a steep decline ... - Boston Globe,

NitroMed stock hits low on 4Q loss Mar 2, 2006
2 12:44 PM ET NitroMed Inc., maker of BiDil, a drug that combats cardiovascular disease in African Americans, on Thursday reported a wider fourth-quarter loss ... - BusinessWeek

NitroMed stock hits low on 4Q loss Mar 2, 2006
...in sales. The Lexington-based company is the maker of BiDil, a drug that combats cardiovascular disease in African Americans. The ... - Eyewitness News,

NitroMed Stock Hits Low on 4Q Loss Mar 2, 2006
LEXINGTON, Mass. (AP) - NitroMed Inc., maker of BiDil, a drug that combats cardiovascular disease in African Americans, on Thursday reported a wider fourth ... - MSN Money

NitroMed to Host Fourth Quarter and Year End 2005 Earnings Call ... Feb 22, 2006
NitroMed of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine ... - PharmaLive.com (press release),

GUEST EDITORIAL: Racial Profiling: Not Always a Bad Thing Feb 9, 2006
The US Food and Drug Administration this year officially approved the drug BiDil after initially rejecting it in 1997. ... BiDil enhances nitric oxide levels. ... - Chicago Defender,

Drug, biotech stocks slip into negative territory Mar 3, 2006
Analysts at JP Morgan lowered their rating of the stock from overweight to neutral citing concerns over sales of its cardiac drug BiDil. - Investor's Business Daily (subscription)

Rotarix Approved In Europe; Avant Due $40M At Launch Feb 27, 2006
Although she did not cite the example, BiDil, a heart-failure treatment directed at black patients from NitroMed Inc., of Lexington, Mass., won FDA approval in ... - BioWorld Online (subscription),

340B Prime Vendor Program Adds NitroMed, Inc. to Growing List of ... Feb 2, 2006
NitroMed will participate by providing BiDilÂ®, indicated for the treatment of heart failure in self-identified black patients. ... - Market Wire (press release)

Smoking Out Cliches About Race Feb 2, 2006
But study also has political implications. It rekindles a story line that BiDil brought into the spotlight recently. Approved by ... - American Enterprise Institute,

(PRN) - Taxpayers and State Pensioners Pay the Price for Energy ... Feb 23, 2006
...[+]. (PRN) - Multimedia News Release - Heart Failure Society Supports the Use of BiDil(R) as Part of Standard Therapy for Symptomatic Heart Failure in African ... - Bolsamania.com,

Singular focus Feb 5, 2006
...that vision. Last year, the US Food and Drug Administration approved BiDil, a treatment for heart failure from NitroMed Inc. of ... - Worcester Telegram (subscription),

GUEST EDITORIAL: Racial Profiling: Not Always a Bad Thing 09 Feb 2006
The US Food and Drug Administration this year officially approved the drug BiDil after initially rejecting it in 1997. ... BiDil enhances nitric oxide levels. ... - Chicago Defender,

NitroMed to Present at BIO CEO & Investor Conference; February 14 ... Feb 7, 2006
Ph.D., NitroMed's President and Chief Executive Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide ... - Genetic Engineering News,

NitroMed $62.5M Placement Supporting Growth Of BiDil Jan 25, 2006
The Lexington, Mass.-based company intends to use the proceeds for general corporate purposes, including commercializing BiDil (isosorbide dinitrate ... - BioWorld Online (subscription),

NitroMed Announces Optimization of BiDil(R) Contract Sales Force Jan 20, 2006
NTMD) announced today that the Company's agreement with Publicis Selling Solutions has been modified to now staff 144 of the original 195 BiDil(R) (isosorbide ... - Genetic Engineering News,

NitroMed Announces Sale of Common Stock Jan 25, 2006
...the financing will be used for general corporate purposes, including the continued commercial launch of NitroMed's first marketed product, BiDil(R) (isosorbide ... - Genetic Engineering News,

Gerald W. Bruce Joins NitroMed as Vice President, Sales Jan 17, 2006
Mr. Bruce's early focus will be on the continued field launch of BiDil(R) (isosorbide dinitrate/hydralazine), NitroMed's first marketed product, the ... - Genetic Engineering News,

Drug is 1st OK'd for a specific race Jan 9, 2006
...that race. The drug, BiDil, is the first medicine approved by the US Food and Drug Administration for a specific race. Health officials ... - Charlotte Observer,

NitroMed to raise $58.6M in stock offering Jan 26, 2006
The money will, in part, help pay for the company's ongoing commercial launch of BiDil, its treatment for black patients with heart failure. ... - Boston Business Journal,

NitroMed Sells Stock Jan 25, 2006
...will be used for general corporate purposes, including the continued commercial launch of NitroMed's first marketed product, BiDil (isosorbide dinitrate ... - TheStreet.com

NitroMed Promotes Michael Sabolinski, MD to the Position of Chief ... Jan 7, 2006
...various research, clinical and marketing efforts, and participate in certain key decision making processes relative to the development of BiDil(R) (isosorbide ... - New Age Media Concepts (press release)

Tech Briefs Jan 30, 2006
...cardiovascular diseases. It is developing a drug called BiDil, which treats African-American patients with heart failure. The drug ... - Lowell Sun,

Replaying the game of race science Jan 29, 2006
His case has the implicit support of the US Food and Drug Administration, which has approved a heart drug, BiDil, that is intended specifically for black people ... - The Age,

Sickle-cell treatment requires healing historical wounds Jan 19, 2006
Makers of the heart drug BiDil, approved specifically for treatment of heart-failure symptoms in black patients, also had difficulty enlisting black patients ... - Savannah Morning News,

Study touts targeted drug ads Jan 11, 2006
This new, more targeted form of medicine is just beginning to emerge as a field, and BiDil a drug targeted specifically toward blacks, just passed FDA scrutiny ... - Daily Pennsylvanian,

Revisiting Race in a Genomic Age: A Public Forum on Race-based ... Jan 9, 2006
This past June, the FDA approved the antihypertensive drug BiDil for the treatment of heart failure in self-identified African-American patients, setting a new ... - Stanford Report

Biotechnology Industry Ends 2005 with Breakthrough Product ... Jan 18, 2006
...in a specific race. NitroMed's BiDil, approved in June, is a heart failure treatment for African Americans. Some orphan drugs approved ... - Yahoo! News (press release)

Columbia doctor supports heart medication that is aimed at blacks 11 Dec 2005
Yet the drug combination called BiDil was federally approved in June, specifically for treating heart failure symptoms in black patients. ... - The State,

FDA Approves Heart Drug for Black Patients Dec 10, 2005
When added to standard heart failure therapy, BiDil dramatically reduces death and hospitalization in blacks. BiDil is a combination ... - Community Dispatch (press release)

BiDil Data to be Presented at American Heart Association ... Nov 11, 2005
...(NASDAQ: NTMD) announced today that it will present several oral abstracts that feature post-approval analyses of BiDil(R) (isosorbide dinitrate/hydralazine HCI ... - PharmaLive.com (press release),

BiDil(R) Data to be Presented at American Heart Association ... Nov 11, 2005
11, 2005--NitroMed, Inc. (NASDAQ: NTMD) announced today that it will present several oral abstracts that feature post-approval analyses of BiDil(R) (isosorbide ... - Business Wire (press release),

African Americans With Cardiovascular Problems to Get Free ... Dec 5, 2005
...using Perfusia-SR." The availability of Perfusia-SR is especially noteworthy given the recent controversy regarding the pharmaceutical drug BiDil earlier this ... - PR Newswire (press release),

Burrell Named Consumer Agency of Record for NitroMed; Account ... Nov 27, 2005
NitroMed with integrated communications services to increase brand awareness and patient education in support of the company's launch of BiDil(R) (isosorbide ... - dBusinessNews Chicago (press release),

Discriminating Medicine Nov 18, 2005
Earlier this year, the FDA approved BiDil as a drug for the treatment of heart failure in self-identified black patients. Since ... - Reason Online

Gene tied to racial variation in heart attack risk Firm says it ... Nov 11, 2005
Last year, a drug called BiDil evoked mixed reactions after it was shown to sharply reduce heart attacks among African Americans. ... - San Francisco Chronicle,

Blacks at risk for heart attacks by more than 250 percent Nov 16, 2005
Last year, US drug regulators approved BiDiL after they discovered a forty-three percent decrease in deaths of Black patients. BiDiL ... - Amsterdam News,

Cramer's 'Mad Money' Recap: The Latin Beat Nov 7, 2005
NitroMed, which Cramer recommended selling into hype this summer after BiDil, the company's treatment for congestive heart failure in African-Americans was ... - TheStreet.com

Scientists find variant of gene they say increases risk of heart ... Nov 10, 2005
...approval. Last year, a drug called BiDil evoked mixed reactions after it was shown to sharply reduce heart attacks among black people. ... - Minneapolis Star Tribune (subscription),

There hasn't been a new drug approved to treat lupus in 40 years. Nov 13, 2005
...just that subset of people. NitroMed Inc. won FDA approval for its drug, BiDil, doing just that. The Lexington company tested the ... - Boston Globe,

Communications Media Announces Promotions Nov 15, 2005
...a planning role for the Taro Pharmaceutical accounts and an assistant planner role for Bristol-Myers Squibbâ€™s Orencia & Baraclude and NitroMedâ€™s BiDil. ... - PharmaLive.com (press release),

NitroMed Presents BiDil Data on Reverse Remodeling in Heart ... Sep 21, 2005
African American Heart Failure Trial (A-HeFT) which was co-sponsored by NitroMed and the Association of Black Cardiologists, suggest that BiDil(R) (isosorbide ... - PharmaLive.com (press release),

UK speakers question companyâ€™s motive behind the â€˜African ... Oct 5, 2005
UK speakers are questioning the whether the new drug, BiDil, which is being used to treat specifically African-Americans suffering from heart-failure should be ... - Black Britain,

Researchers Seek to Determine Whether Genetic Variations May ... Sep 21, 2005
...may determine that genetic variations influencing cellular levels of nitric oxide (NO) production affect a patient's clinical response to BiDil(R) (isosorbide ... - PharmaLive.com (press release),

Welton O'Neal, Jr., Pharm.D. Joins NitroMed as Vice President ... Sep 12, 2005
...announced that Welton O'Neal, Jr., Pharm.D., has joined the company as Vice President Medical Affairs, a position to support the launch of BiDil(R) (isosorbide ... - PharmaLive.com (press release),

NitroMed to Present at UBS Global Life Sciences Conference ... Sep 20, 2005
Dr. Loberg will present a NitroMed corporate overview and BiDil(R) progress report on Monday, September 26, at 3:30 pm (ET). The ... - Genetic Engineering News,

Jane A. Kramer Joins NitroMed as Vice President, Corporate ... Sep 22, 2005
...as the Company addresses an ever wider circle of investors, members of the press and government since the launch of our heart failure drug, BiDil(R), in July. ... - Business Wire (press release),

DNA chips bring personalized medicine to China Oct 5, 2005
Nitromed Inc received clearance from the US Food and Drug Administration in June to market BiDil as a treatment for heart failure in African-American patients. ... - Asia Times Online,

Best Treatments: Managing Heart Failure Sep 24, 2005
...but respond better to a combination of two older drugsâ€”hydralazine and nitroglycerinâ€”that are now being marketed as a single pill under the name BiDil. ... - Newsweek

Operation Healthy Us, Part Three: Whoâ€™s Lobbying for Black ... Sep 15, 2005
BiDil, which was recently approved by the US Food and Drug Administration, was manufactured specifically to treat blacks for heart failure. ... - Black America Web,

Association of Black Cardiologists Providing its Unique Medical ... Sep 8, 2005
ABC is also collaborating with NitroMed, the maker of the heart failure medicine known as BiDil. NitroMed has committed to making ... - Business Wire (press release),

INDIVIDUALIZED MEDICINES OFFER HOPE FOR NARROWING HEALTH ... Sep 2, 2005
Why? Because the drug, BiDil, was approved by the US Food and Drug Administration (FDA) exclusively for â€œself-identified blacksâ€? with heart failure. ... - Eurweb.com,

FDA Standards â€” Good Enough for Government Work? Sep 7, 2005
The FDA recently approved BiDil, a branded combination of hydralazine and isosorbide dinitrate, on the grounds that it was uniquely effective in treating ... - New England Journal of Medicine (subscription),

Use of BiDil(R) Supported in Updated Heart Failure Guidelines Aug 17, 2005
American College of Cardiology and American Heart Association Guidelines Support Use of BiDil, a Proprietary Fixed-Dose Combination, for the Treatment of Heart ... - PR Newswire (press release),

Use of BiDil Supported in Updated Heart Failure Guidelines Aug 17, 2005
AHA) support the combined use of isosorbide dinitrate and hydralazine, now available as a proprietary fixed-dose formulation known as BiDil(R) (isosorbide ... - PharmaLive.com (press release),

NitroMed's BiDil receives support from medical groups Aug 17, 2005
The American College of Cardiology and the American Heart Association released updated guidelines on Tuesday supporting the use of the company's BiDil drug as ... - Boston Business Journal,

NitroMed to Present at Bear Stearns' Healthcare Conference ... Sep 7, 2005
Dr. Loberg will present a NitroMed corporate overview and BiDil(R) progress report on Monday, September 12, at 2:00 pm (ET). The ... - PharmaLive.com (press release),

GLENN ELLIS' STRATEGIES FOR WELL BEING: Should We Worry About Race ... Aug 25, 2005
The US Food and Drug Administration approved the worldâ€™s first â€œethnicâ€? medication, BiDil, for "self-identified African Americans," leaving room for ... - Eurweb.com,

FDA Taken to Task, Again Sep 7, 2005
Avorn says. And then there is the example of BiDil, recently approved to treat congestive heart failure in black patients. That ... - Forbes

Teenage and adult use of speed studied Aug 29, 2005
FDA approves heart drug aimed at blacks (June 24, 2005) -- The US Food and Drug Administration has approved the controversial drug BiDil to treat heart failure ... - Science Daily (press release)

MEDICINE TAILORED TO SPECIFIC GROUPS Sep 2, 2005
Patients of various races may respond to treatments differently; for example, BiDil, a new drug for treatment of severe heart failure, has been shown in ... - National Center for Policy Analysis,

So, what does it mean to be a Patel? Aug 14, 2005
Researchers have devised drugs aimed at a specific ethnic population (BiDil, a drug for congestive heart failure, works exclusively on Blacks). ... - Economic Times,

New Herbal Solution Helps African-American Smokers Quit Aug 23, 2005
...be used by anyone of any ethnicity. The product is NOT like BiDil - a new heart medicine designed solely for African-Americans. - BlackNews.com (press release),

Law - Prominent IP attorney joins Venable from Wilmer Cutler's DC ... Aug 23, 2005
Recent achievements include obtaining patents covering methods of using BiDilÂ®, a treatment for African-American heart failure patients; the drug received FDA ... - Lawfuel (press release),

MEDICINE TO FIT YOUR GENES Aug 26, 2005
The Food and Drug Administration's (FDA's) approval of the heart drug BiDil marks a new understanding of health disparities, say John J. Cohrssen and J. Donald ... - National Center for Policy Analysis,

Good Old Boys Aug 10, 2005
The Cleveland Clinic medical director chaired the FDA panel that recommended approval of BiDil, the first pill aimed exclusively at one race. ... - Cleveland Scene Weekly,

Race, DNA talks part of UDâ€™s campus agenda Aug 10, 2005
In June, the Federal Drug Administration approved the first race-based drug, BiDil, manufactured to treat African Americans with heart disease. ... - Cincinnati Catholic Telegraph,

A death sentence for blacks Aug 19, 2005
...are striking. An example this year was the Food and Drug Administrationâ€™s approval of the cardiovascular drug BiDil. The first ... - Kansas City Star,

Startups Raise Nearly $30M Aug 10, 2005
When the US Food and Drug Administration approved BiDil to treat heart failure in black patients in June, it opened the door for drug companies looking to ... - Red Herring,

Clinical trials fall short of minority patients Aug 14, 2005
In June, the US Food and Drug Administration app-roved a new heart failure drug called BiDil for use in black patients after research found it benefited blacks ... - Bryan College Station Eagle,